{"id":494,"date":"2008-08-29T16:18:18","date_gmt":"2008-08-29T15:18:18","guid":{"rendered":"http:\/\/localhost\/new\/htb\/?p=494"},"modified":"2013-08-27T16:21:07","modified_gmt":"2013-08-27T16:21:07","slug":"failure-of-step-leads-tag-to-criticise-the-proposed-pave100a-vaccine-trial","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/494","title":{"rendered":"Failure of STEP leads TAG to criticise the proposed PAVE100A vaccine trial"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>The failure of STEP trial, using Merck&#8217;s adenovirus serotype 5 (Ad5)-based HIV vaccine, has implications for using another Ad5 candidate in the proposed PAVE100A Phase IIb efficacy trial.<\/strong><\/p>\n<p>The STEP trial neither reduced infection or post-infection viral load, and potentially increased infection rates among a subset of trial participants.<\/p>\n<p>Treatment Action Group (TAG), a influential community-based policy think-tank published a Position Statement that raises serious concerns about continuing with the PAVE100A trial.<\/p>\n<p>This includes an analysis of the scientific likely hood that this new candidate will produce a different response, and questioning both the relevance and safety of such a restricted study population:the PAVE trial is limiting recruitment to circumcised gay men with no detectable antibody responses to Ad5.<\/p>\n<p>TAG proposes abandoning plans for this particular clinical trial and Ad5 vaccine candidate in favour of supporting research to rapidly address two key issues:<\/p>\n<ol>\n<li>The use of an alternate vector or DNA approach for the boosting immunisation that could be studied in a broader population.<\/li>\n<li>Inducing broader responses to proteins contained in the vaccine, particularly HIV-1 Gag.<\/li>\n<\/ol>\n<p>They argue against spending human and fiscal resources on PAVE100A, and instead suggest focusing on improving T cell based immunogens so they can be studied in a broader population with a greater chance of success.<\/p>\n<p>Source: TAG Basic Science Blog (30 May 2008)<\/p>\n<p>The full statement &#8220;TAG position statement on the proposed PAVE100A vaccine trial&#8221; is available online: <a href=\"http:\/\/www.aidsinfonyc.org\/tag\"><br \/>\nhttp:\/\/www.aidsinfonyc.org\/tag<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base The failure of STEP trial, using Merck&#8217;s adenovirus serotype 5 (Ad5)-based HIV vaccine, has implications for using another Ad5 candidate in the proposed PAVE100A Phase IIb efficacy trial. The STEP trial neither reduced infection or post-infection &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-494","post","type-post","status-publish","format-standard","hentry","category-basic-science-and-immunology"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=494"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/494\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}